VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds through a private placement. The company issued 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants at a combined price of $0.85 per share. The warrants, which are exercisable following shareholder approval and expire five years after their initial exercise date, carry an exercise price of $0.85 per share. Additionally, subject to shareholder approval, VivoSim agreed to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, subject to customary closing conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction. For more details, see the full press release at https://ibn.fm/7Ov0B.
This capital raise comes at a pivotal time for VivoSim, a pharmaceutical and biotechnology services company focused on providing testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine. The company offers partners liver and intestinal toxicology insights using new approach methodologies (NAM) models. VivoSim anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration's (FDA) roadmap to refine animal testing requirements in favor of these non-animal NAM methods. The infusion of capital will support the company's working capital needs and general corporate purposes as it positions itself to capitalize on regulatory shifts toward alternative testing methods.
The private placement's structure, including the low exercise price of warrants and the amendment of existing warrants, signals a strategic move to attract institutional investment while managing dilution. The healthcare-focused investor's participation indicates confidence in VivoSim's technology and market potential. As the FDA continues to promote NAMs, companies like VivoSim are well-positioned to benefit from the transition away from traditional animal testing. The company operates from San Diego, CA, and more information is available at https://vivosim.ai/.
This announcement underscores the growing importance of alternative testing methods in the pharmaceutical industry, and VivoSim's ability to secure funding from a specialized investor highlights the perceived value of its approach. The proceeds from the placement will enable the company to advance its operations and potentially expand its service offerings, capitalizing on the regulatory tailwinds.
